Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)

Diabetes Care

Volumn 28, Issue 5, 2005, Pages 1151-1157

  Sever, Peter S ^a   Poulter, Neil R ^a   Dahlöf, Björn ^b   Wedel, Hans ^c   Collins, Rory ^d   Beevers, Gareth ^e   Caulfield, Mark ^f   Kjeldsen, Sverre E ^g,h   Kristinsson, Arni ⁱ   McInnes, Gordon T ^j   Mehlsen, Jesper ^k   Nieminen, Markku ^l   O'Brien, Eoin ^m   Ostergren, Jan ⁿ  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Nordiska Halsovardshagskolan   (Sweden)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e CITY HOSPITAL   (United Kingdom)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^g UNIVERSITY OF MICHIGAN   (United States)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

ⁱ LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k FREDERIKSBERG HOSPITAL   (Denmark)

^l HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^m BEAUMONT HOSPITAL   (Ireland)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT OUTCOME;

ADULT; AGED; CEREBROVASCULAR ACCIDENT; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PYRROLES; RISK FACTORS;

EID: 20944448451     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.5.1151     Document Type: Article

References (20)

1. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham Study. JAMA 241:2035-2038, 1979
2. The Hypertension in Diabetes Study Group: Hypertension in Diabetes Study (HDS): 1. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 11:308-317, 1993
3. Stamler J: Established major coronary risk factors. In Coronary Heart Disease: From Aetiology to Public Health. Marmot M, Elliott P, Eds. Oxford, U.K., Oxford University Press, 1992
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D, Multiple Risk Factor Intervention Trial Research Group: Diabetes, other risk factors and 12 year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16:434-444, 1993
5. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study 27: plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 20:1638-1687, 1997
6. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 19:1139-1147, 2001
7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1307, 1995
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stem EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with Iovastatin in men and woman with average cholesterol levels. Results of AFCAPS/ TexCAPS. JAMA 279:1615-1622, 1998
9. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002
10. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016, 2003
11. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004
12. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158, 2003
13. Albert KGMM, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO Consultation. Diabet Med 15:539-553, 1998
14. UK Prospective Diabetes Study Group (UKPDS): Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
15. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998
16. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs. usual care. JAMA 288:2998-3007, 2002
17. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, the Scandinavian Simvastatin Study Group (4S): Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 20:614-620, 1997
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001
19. Guidelines Committee, 2003 European Society of Hypertension: European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053, 2003
20. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S, the British Hypertension Society: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society 2004-BHS IV. J Hum Hypertens 18:139-185, 2004